{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:28:29Z","timestamp":1788553709946,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15061-4","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:24:03Z","timestamp":1760703843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of stereotactic body radiation therapy combined with targeted agents and immunotherapies in hepatocellular carcinoma: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Shuaihao","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suqin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"5","key":"15061_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/biom12050645","volume":"12","author":"S Khare","year":"2022","unstructured":"Khare S, Khare T, Ramanathan R, Ibdah JA. Hepatocellular carcinoma: the role of microRNAs. Biomolecules. 2022;12(5):645. https:\/\/doi.org\/10.3390\/biom12050645.","journal-title":"Biomolecules"},{"issue":"1","key":"15061_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cld.2022.08.004","volume":"27","author":"P Ganesan","year":"2023","unstructured":"Ganesan P, Kulik LM. Hepatocellular carcinoma: new developments. Clin Liver Dis. 2023;27(1):85\u2013102. https:\/\/doi.org\/10.1016\/j.cld.2022.08.004.","journal-title":"Clin Liver Dis"},{"key":"15061_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acr.2020.10.001","volume":"149","author":"S Chidambaranathan-Reghupaty","year":"2021","unstructured":"Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1\u201361. https:\/\/doi.org\/10.1016\/bs.acr.2020.10.001.","journal-title":"Adv Cancer Res"},{"issue":"3","key":"15061_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.gendis.2020.02.001","volume":"7","author":"H Chen","year":"2020","unstructured":"Chen H, Jia W. Progress in hepatectomy for hepatocellular carcinoma and peri-operation management. Genes Dis. 2020;7(3):320\u20137. https:\/\/doi.org\/10.1016\/j.gendis.2020.02.001.","journal-title":"Genes Dis"},{"issue":"2","key":"15061_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3350\/cmh.2023.0051","volume":"29","author":"JC Ahn","year":"2023","unstructured":"Ahn JC, Tran NH, Yang JD. Systemic therapy in advanced hepatocellular carcinoma. Clin Mol Hepatol. 2023;29(2):516\u20139. https:\/\/doi.org\/10.3350\/cmh.2023.0051.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"15061_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cac2.12414","volume":"43","author":"JW Eun","year":"2023","unstructured":"Eun JW, Yoon JH, Ahn HR, Kim S, Kim YB, Lim SB, et al. Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer Commun. 2023;43(4):455\u201379. https:\/\/doi.org\/10.1002\/cac2.12414.","journal-title":"Cancer Commun"},{"issue":"8","key":"15061_CR7","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2468-1253(23)00147-4","volume":"8","author":"M Pinter","year":"2023","unstructured":"Pinter M, Scheiner B, Pinato DJ. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice. Lancet Gastroenterol Hepatol. 2023;8(8):760\u201370. https:\/\/doi.org\/10.1016\/S2468-1253(23)00147-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"20","key":"15061_CR8","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"14","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;14(20):1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med"},{"issue":"18","key":"15061_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184383","volume":"14","author":"T Kimura","year":"2022","unstructured":"Kimura T, Fujiwara T, Kameoka T, Adachi Y, Kariya S. The current role of stereotactic body radiation therapy (SBRT) in hepatocellular carcinoma (HCC). Cancers (Basel). 2022;14(18):4383. https:\/\/doi.org\/10.3390\/cancers14184383.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"15061_CR10","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","volume":"26","author":"G Marvaso","year":"2025","unstructured":"Marvaso G, Corrao G, Zaffaroni M, Vincini MG, Lorubbio C, Gandini S, et al. ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. Lancet Oncol. 2025;26(3):300\u201311. https:\/\/doi.org\/10.1016\/S1470-2045(24)00730-7.","journal-title":"Lancet Oncol"},{"key":"15061_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109681","volume":"184","author":"P Peng","year":"2023","unstructured":"Peng P, Gong J, Zhang Y, Zhou S, Li Y, Han G, et al. EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV non-small cell lung cancer (NSCLC): a prospective, multicenter, randomized, controlled phase II study. Radiother Oncol. 2023;184:109681. https:\/\/doi.org\/10.1016\/j.radonc.2023.109681.","journal-title":"Radiother Oncol"},{"issue":"2","key":"15061_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","volume":"11","author":"LA Dawson","year":"2025","unstructured":"Dawson LA, Winter KA, Knox JJ, Zhu AX, Krishnan S, Guha C, et al. Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: the NRG oncology\/RTOG 1112 phase 3 randomized clinical trial. JAMA Oncol. 2025;11(2):136\u201344. https:\/\/doi.org\/10.1001\/jamaoncol.2024.5403.","journal-title":"JAMA Oncol"},{"issue":"20","key":"15061_CR13","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.1158\/1078-0432.CCR-22-2592","volume":"29","author":"Y Hu","year":"2023","unstructured":"Hu Y, Zhou M, Tang J, Li S, Liu H, Hu J, et al. Efficacy and safety of stereotactic body radiotherapy combined with Camrelizumab and Apatinib in patients with hepatocellular carcinoma with portal vein tumor thrombus. Clin Cancer Res. 2023;29(20):4088\u201397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2592.","journal-title":"Clin Cancer Res"},{"key":"15061_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.839605","volume":"12","author":"YJ Xiang","year":"2022","unstructured":"Xiang YJ, Wang K, Zheng YT, Feng S, Yu HM, Li XW, et al. Effects of stereotactic body radiation therapy plus PD-1 inhibitors for patients with transarterial chemoembolization refractory. Front Oncol. 2022;12:839605. https:\/\/doi.org\/10.3389\/fonc.2022.839605.","journal-title":"Front Oncol"},{"issue":"15","key":"15061_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153619","volume":"14","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Li C, Liao W, Huang Y, Wang Z. A combination of Sorafenib, an immune checkpoint inhibitor, TACE and stereotactic body radiation therapy versus Sorafenib and TACE in advanced hepatocellular carcinoma accompanied by portal vein tumor thrombus. Cancers (Basel). 2022;14(15):3619. https:\/\/doi.org\/10.3390\/cancers14153619.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"15061_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-023-02270-z","volume":"18","author":"X Ji","year":"2023","unstructured":"Ji X, Xu Z, Sun J, Li W, Duan X, Wang Q. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study. Radiat Oncol. 2023;18(1):101. https:\/\/doi.org\/10.1186\/s13014-023-02270-z.","journal-title":"Radiat Oncol"},{"issue":"13","key":"15061_CR17","doi-asserted-by":"publisher","first-page":"1290691","DOI":"10.3389\/fonc.2023.1290691","volume":"27","author":"A Piening","year":"2023","unstructured":"Piening A, Swaminath A, Dombrowski J, Teague RM, Al-Hammadi N, Shahi J. Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic body radiation therapy or systemic therapy alone. Front Oncol. 2023;27(13):1290691. https:\/\/doi.org\/10.3389\/fonc.2023.1290691.","journal-title":"Front Oncol"},{"key":"15061_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01589","volume":"10","author":"Y Hu","year":"2020","unstructured":"Hu Y, Qin T, Li S, Zhang T, Xue J. Efficacy and safety of SBRT combined with Camrelizumab and Apatinib in HCC patients with PVTT: study protocol of a randomized controlled trial. Front Oncol. 2020;10:1589. https:\/\/doi.org\/10.3389\/fonc.2020.01589.","journal-title":"Front Oncol"},{"issue":"16","key":"15061_CR19","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.3969\/j.issn.1009-5519.2014.16.024","volume":"30","author":"X Li","year":"2014","unstructured":"Li X, Yan W. Recent efficacy analysis of stereotactic radiotherapy combined with sorafenib for recurrent liver cancer. Journal of Modern Medicine & Health. 2014;30(16):2456\u20138. https:\/\/doi.org\/10.3969\/j.issn.1009-5519.2014.16.024.","journal-title":"Journal of Modern Medicine & Health"},{"key":"15061_CR20","doi-asserted-by":"publisher","unstructured":"Zhu Z, Yan W, Li X, et al. Clinical efficacy and safety of targeted drug sorafenib combined with stereotactic radiotherapy in treating lung metastasis of hepatocellular carcinoma. J Guangxi Med Univ. 2020;37(6).\u00a0https:\/\/doi.org\/10.16190\/j.cnki.45-1211\/r.2020.06.027.","DOI":"10.16190\/j.cnki.45-1211\/r.2020.06.027"},{"key":"15061_CR21","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.947317","volume":"26","author":"C Hua","year":"2025","unstructured":"Hua C, Huang S, Ding B, Chen J, Ding C. Efficacy of hepatic artery infusion chemotherapy with bevacizumab and sintilimab in advanced hepatocellular carcinoma: a case report. Am J Case Rep. 2025;26:e947317. https:\/\/doi.org\/10.12659\/AJCR.947317.","journal-title":"Am J Case Rep"},{"issue":"2","key":"15061_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006493","volume":"11","author":"X Wang","year":"2023","unstructured":"Wang X, Zhang Q, Zhou J, Xiao Z, Liu J, Deng S, et al. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma. J Immunother Cancer. 2023;11(2):e006493. https:\/\/doi.org\/10.1136\/jitc-2022-006493.","journal-title":"J Immunother Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15061-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15061-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15061-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:24:05Z","timestamp":1760703845000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15061-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15061"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15061-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1602"}}